IBI351

DRUG4 trials

Sponsors

Innovent Biologics (Suzhou) Co. Ltd.

Conditions

Advanced Non-Small Cell Lung CancerColorectal CancerHealthy Subjects

Phase 1

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Innovent Biologics (Suzhou) Co. Ltd.Colorectal Cancer

Start: 2022-08-18End: 2024-09-30Target: 80Updated: 2022-09-30

Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

RecruitingNCT05504278

Innovent Biologics (Suzhou) Co. Ltd.Advanced Non-Small Cell Lung Cancer

Start: 2022-09-20End: 2027-07-31Target: 144Updated: 2025-01-27

A Study of IBI351 in Healthy Subjects

CompletedNCT05688124

Innovent Biologics (Suzhou) Co. Ltd.Healthy Subjects

Start: 2023-02-16End: 2023-10-16Updated: 2023-10-24

A Study of IBI351 in Healthy Subjects

CompletedNCT05699993

Innovent Biologics (Suzhou) Co. Ltd.Healthy Subjects

Start: 2023-03-10End: 2023-10-16Updated: 2023-10-24

Related Papers

Efficacy and safety of IBI351 (fulzerasib) monotherapy in KRAS<sup>G12C</sup> inhibitor-naïve Chinese patients with KRAS<sup>G12C</sup>-mutated metastatic colorectal cancer: a pooled analysis from phase I part of two studies.

2025-07-252 citations

Efficacy and safety of IBI351 (GFH925) monotherapy in metastatic colorectal cancer harboring KRAS<sup>G12C</sup> mutation: Preliminary results from a pooled analysis of two phase I studies.

Journal of Clinical Oncology2023-06-018 citations